Studies toward the discovery of the next generation of antidepressants. Part 2: incorporating a 5-HT(1A) antagonist component into a class of serotonin reuptake inhibitors.

[1]  B. Harrison,et al.  A new efficient synthesis of 3-(4-pyridinyl)methylindoles , 2001 .

[2]  D. Smith,et al.  Studies towards the next generation of antidepressants. Part 1: Indolylcyclohexylamines as potent serotonin reuptake inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[3]  A. Monge,et al.  New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants. , 2001, Journal of medicinal chemistry.

[4]  A. Monge,et al.  Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual mode of action: serotonin reuptake inhibition and 5-HT1A receptor antagonism. , 2000, Farmaco.

[5]  R. Schreiber,et al.  S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties. IV. A drug discrimination comparison with clozapine. , 1999, The Journal of pharmacology and experimental therapeutics.

[6]  P. Pauwels,et al.  Design and synthesis of new potent, silent 5-HT1A antagonists by covalent coupling of aminopropanol derivatives with selective serotonin reuptake inhibitors. , 1998, Bioorganic & medicinal chemistry letters.

[7]  J. Dunlop,et al.  Characterization of 5-HT1A receptor functional coupling in cells expressing the human 5-HT1A receptor as assessed with the cytosensor microphysiometer. , 1998, Journal of pharmacological and toxicological methods.

[8]  K. Marquis,et al.  New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans. , 1997, Journal of medicinal chemistry.

[9]  F. Artigas,et al.  Preferential Potentiation of the Effects of Serotonin Uptake Inhibitors by 5‐HT1A Receptor Antagonists in the Dorsal Raphe Pathway: Role of Somatodendritic Autoreceptors , 1997, Journal of neurochemistry.

[10]  T. Yamaguchi,et al.  N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor. , 1997, Journal of medicinal chemistry.

[11]  C. Montigny,et al.  Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists , 1996, Trends in Neurosciences.

[12]  F. Artigas,et al.  The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain , 1996, Neuroscience Letters.

[13]  J. Catravas,et al.  Cyclic AMP-independent Up-regulation of the Human Serotonin Transporter by Staurosporine in Choriocarcinoma Cells (*) , 1995, The Journal of Biological Chemistry.

[14]  P. Blier,et al.  Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. , 1995, Journal of clinical psychopharmacology.

[15]  V. Pérez,et al.  Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. , 1994, Archives of general psychiatry.

[16]  S. Cheetham,et al.  [3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: Effect of administration of various antidepressant treatments , 1993, Neuropharmacology.

[17]  S. Lazareno,et al.  Pharmacological characterization of acetylcholine‐stimulated [35S]‐GTPγS binding mediated by human muscarinic m1–m4 receptors: antagonist studies , 1993, British journal of pharmacology.

[18]  F. Artigas.  5-HT and antidepressants: new views from microdialysis studies. , 1993, Trends in pharmacological sciences.

[19]  F. Graeff,et al.  Clinical implication of microdialysis findings. , 1993, Trends in pharmacological sciences.

[20]  S. Mignani,et al.  New indole derivatives as potent and selective serotonin uptake inhibitors. , 1993, Journal of medicinal chemistry.

[21]  M. Safar,et al.  S14063: a new potent 5-HT1A receptor antagonist devoid of β-adrenoceptor blocidng properties☆ , 1991 .

[22]  D. Nelson,et al.  Molecular determinants for recognition of RU 24969 analogs at central 5-hydroxytryptamine recognition sites: use of a bilinear function and substituent volumes to describe steric fit. , 1988, Molecular pharmacology.

[23]  D. Middlemiss,et al.  Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor. , 1988, Journal of medicinal chemistry.

[24]  M. Molliver.  Serotonergic Neuronal Systems: What Their Anatomic Organization Tells Us about Function , 1987, Journal of clinical psychopharmacology.

[25]  I. Creese,et al.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding. , 1986, Molecular pharmacology.

[26]  M. Hamon,et al.  [3H]8‐Hydroxy‐2‐(Di‐n‐Propylamino)Tetralin Binding to Pre‐ and Postsynaptic 5‐Hydroxytryptamine Sites in Various Regions of the Rat Brain , 1985, Journal of neurochemistry.

[27]  O. Mitsunobu.  The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products , 1981 .

[28]  G. Le Fur,et al.  3-(4-Piperidinylalkyl)indoles, selective inhibitors of neuronal 5-hydroxytryptamine uptake. , 1980, Journal of medicinal chemistry.